5 research outputs found
Methotrexate Gold Nanocarriers: Loading and Release Study: Its Activity in Colon and Lung Cancer Cells
In the present study, the synthesis of gold nanoparticles (AuNPs) loaded with methotrexate
(MTX) has been carried out in order to obtain controlled size and monodispersed nanocarriers of
around 20 nm. The characterization study shows metallic AuNPs with MTX polydispersed on
the surface. MTX is linked by the replacement of citrate by the MTX carboxyl group. The drug
release profiles show faster MTX release when it is conjugated, which leads to the best control of
plasma concentration. Moreover, the enhanced release observed at pH 5 could take advantage of
the pH gradients that exist in tumor microenvironments to achieve high local drug concentrations.
AuNP–MTX conjugates were tested by flow cytometry against lung (A-549) and colon (HTC-116)
cancer cell lines. Results for A-549 showed a weaker dose–response e ect than for colon cancer ones.
This could be related to the presence of folate receptors in line HTC-116 in comparison to line A-549,
supporting the specific uptake of folate-conjugated AuNP–MTX by folate receptor positive tumor
cells. Conjugates exhibited considerably higher cytotoxic e ects compared with the e ects of equal
doses of free MTX. Annexin V-PI tests sustained the cell death mechanism of apoptosis, which is
normally disabled in cancer cells.Spanish GovernmentJunta de Andalucía
P18-RT-419
Comparative Study of the Oxidative Degradation of Different 4-Aminobenzene Sulfonamides in Aqueous Solution by Sulfite Activation in the Presence of Fe(0), Fe(II), Fe(III) or Fe(VI)
This study is focused on advanced oxidation technologies (AOTs) using the combined
effect of Fe(0–VI)/sulfite systems, that produce mainly SO4 radicals, to remove di erent
4-aminobenzene sulfonamides (SAs), namely sulfamethazine, sulfadiazine, sulfamethizole, from
aqueous solutions. Results obtained showed that neither sulfite nor iron alone is able to degrade
SAs; however, the combined effect depends on the oxidation state of iron species whose effectiveness
to activate sulfite to promote the degradation of SAs increased following this order: Fe(III) < Fe(II)
< Fe(0) < Fe(VI). Using Fe(VI)/sulfite, the complete removal of SAs was obtained in 5 min largely
surpassing the effectiveness of the other three systems. The sulfonamides’ removal percentage was
markedly influenced by sulfite concentration and dissolved oxygen, which improved the generation
of oxidant radicals. Response surface methodology was applied, and a quadratic polynomial model
was obtained, which allowed us to determine the percentage of SAs degradation as a function of
both the iron species and sulfite concentrations. The study of the influence of the water matrix on
these AOTs revealed an inhibition of SAs’ removal percentage when using ground water. This is
probably due to the presence of different anions, such as HCO3
-, Cl-, and SO4
2- in relatively high
concentrations. According to the byproducts identified, the proposed degradation pathways include
hydroxylation, SO2 extrusion, and different bond-cleavage processes. Cytotoxicity of degradation
byproducts, using MTS assay with HEK 293 and J774 cell lines for the first time, did not show an
inhibition in cell proliferation, sustaining the safety of the process.This research was funded by both Ministry of Science and Innovation of Spain, grant number
CTQ2016-80978-C2-1-R, and CONACyT (Mexico), grant number 407494
EuReCa ONE—27 Nations, ONE Europe, ONE Registry A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe
AbstractIntroductionThe aim of the EuReCa ONE study was to determine the incidence, process, and outcome for out of hospital cardiac arrest (OHCA) throughout Europe.MethodsThis was an international, prospective, multi-centre one-month study. Patients who suffered an OHCA during October 2014 who were attended and/or treated by an Emergency Medical Service (EMS) were eligible for inclusion in the study. Data were extracted from national, regional or local registries.ResultsData on 10,682 confirmed OHCAs from 248 regions in 27 countries, covering an estimated population of 174 million. In 7146 (66%) cases, CPR was started by a bystander or by the EMS. The incidence of CPR attempts ranged from 19.0 to 104.0 per 100,000 population per year. 1735 had ROSC on arrival at hospital (25.2%), Overall, 662/6414 (10.3%) in all cases with CPR attempted survived for at least 30 days or to hospital discharge.ConclusionThe results of EuReCa ONE highlight that OHCA is still a major public health problem accounting for a substantial number of deaths in Europe.EuReCa ONE very clearly demonstrates marked differences in the processes for data collection and reported outcomes following OHCA all over Europe. Using these data and analyses, different countries, regions, systems, and concepts can benchmark themselves and may learn from each other to further improve survival following one of our major health care events